Microbes and metabolism: GLP-1, Akkermansia, fatty acids
Gut bacteria ferment fibre into short-chain fatty acids — acetate, propionate, butyrate. These feed the gut wall and signal to cells that release GLP-1, the hormone that slows the stomach and tells the brain you are full. Akkermansia muciniphila, which lives on mucus, strengthens the barrier that keeps this conversation orderly. It is a pathway, not a cure.
Written by: Magnus Larsen · Microbiologist · Science bloggerPublished: Facts checked: What this system is
Metabolism is not only what you eat; it is also what your bacteria make of it. Fibre passes your own enzymes untouched and reaches the colon, where fermenters convert it into short-chain fatty acids. Butyrate is burned by the cells of the gut wall. Propionate travels to the liver. Acetate reaches muscle and fat. All three bind receptors on enteroendocrine cells — the hormone-releasing cells scattered along the gut — which respond by secreting GLP-1 and PYY.
GLP-1 is the hormone that a well-known class of diabetes and weight-loss drugs imitates. Your bacteria have been stimulating the natural version for as long as you have eaten plants.
Akkermansia muciniphila sits in the mucus layer that separates bacteria from the gut wall. By eating mucus, it prompts the wall to make more, thickening the barrier. A thicker barrier means fewer bacterial fragments leaking into the blood — the low-grade inflammation associated with insulin resistance.
The three questions people ask
Can bacteria make me lose weight? In mice, transferring a microbiome transfers a tendency toward leanness or fat. In humans, the effect of any single strain on body weight, where measured, is small. Fibre remains the reliable lever.
Is Akkermansia a probiotic I should take? It is the most studied next-generation candidate, and a pasteurised form has been tested in overweight adults with encouraging safety and metabolic markers. It is early.
Does the microbiome cause diabetes? People with diabetes carry a different community, with fewer butyrate producers. Whether restoring them changes the disease is under trial.
What the science can and cannot say yet
It can say: short-chain fatty acids trigger GLP-1 release; the barrier matters; the composition differs in metabolic disease; diet changes both quickly.
It cannot yet say: whether any bacterial supplement prevents or reverses diabetes or obesity in the long run, or which patients respond. Mouse mechanisms are strong; human outcome trials are few.
Read the encyclopedia of bacteria for the species named here, and the news list for what changed this month.